NeuroSense Therapeutics is preparing to start its Phase 3 PARAGON trial for PrimeC, a treatment for ALS, after FDA clearance. The company is actively securing strategic financing and exploring regulatory approvals, including a planned New Drug Submission in Canada by December 2026, to bring the drug to patients sooner. NeuroSense is also addressing Nasdaq listing compliance and exploring partnerships to support PrimeC's development and commercialization. These efforts aim to accelerate treatment availability for ALS patients while ensuring financial and regulatory readiness.
Primo Brands Corporation received a BUY rating following robust second-quarter 2026 results, improved operating leverage, and a favorable valuation discount. The company raised its 2026 sales guidance to 2–4% growth, driven by strong premium brand pe...
Wistron Corporation's shares fell over 6% after announcing a $1.47 billion global depositary receipt offering to raise funds for raw material purchases. The offering involves 25 million receipts priced at a 5.5% discount, representing about 7.29% of ...
A British man known as Chris reclaimed 61 BTC worth $4.4 million after 12 years of legal battle following the 2014 collapse of Intersango, a UK bitcoin exchange. Initially buying bitcoin in 2011, Chris left his coins in the exchange custody, which sh...
XPENG has started operating the world's first advanced humanoid robot production lines, successfully transitioning from R&D to mass manufacturing. Their humanoid robot, IRON, features high dexterity, AI intelligence, and automotive-grade quality, des...
Lemonade announced that CFO Tim Bixby will participate in the KBW Insurance Conference on September 10 and the FT Partners FinTech Conference on September 15, 2026. His appearances will include one-on-one meetings and fireside chats, with webcasts av...
